News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2020 Early Data Support TAVR in Bicuspid Valves, but Questions Remain Michael O'Riordan March 29, 2020
News Conference News ACC 2020 PARTNER 3: TAVR Now Noninferior to Surgery at 2 Years in Low-Risk Patients Yael L. Maxwell March 29, 2020
News Conference News ACC 2020 A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI Todd Neale March 29, 2020
News Conference News ACC 2018 NOTION: 5-Year Outcomes for TAVR Match SAVR in Low-Risk Patients Shelley Wood March 10, 2018
News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2016 Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes Michael O'Riordan April 07, 2016
News Conference News ACC 2016 Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial Yael L. Maxwell April 03, 2016
News Conference News ACC 2014 ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation Yael L. Maxwell April 03, 2014
News Conference News ACC 2014 CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks L.A. McKeown March 31, 2014
News Conference News ACC 2013 PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device L.A. McKeown March 09, 2013